CD36 immunization in a patient undergoing hematopoietic stem cell transplantation

Abstract

Anti-CD36 antibodies are known to cause a platelet refractory state. We describe a previously unreported case of a 16-year-old female sickle cell disease patient with anti-CD36 antibodies, detected on routine screen prior to hematopoietic stem cell transplantation (HSCT). CD36 platelet antigen typing was negative for both the patient and her HLA-identical donor sibling. Patient plasma was compatible with 48 of 49 apheresis platelets, which were untested and presumably positive for the CD36 antigen. The patient responded adequately to transfusion of crossmatch compatible platelets and successfully underwent HSCT. The presence of anti-CD36 antibodies does not exclude potential candidates from HSCT.

A case of Philadelphia chromosome‐positive acute lymphocytic leukaemia with type I CD36 deficiency

“…For HSCT indications in patients with type I CD36-deficiency with CD36 antibodies, confirming CD36 expression in potential donors is crucial. A CD36-negative patient in the US successfully received a transplant from a CD36-negative sibling [13]. Thus, ideally, CD36-negative donors should be selected for allogeneic (allo-) HSCT in CD36-negative patients with CD36 antibodies.…”

Two cases of platelet transfusion refractoriness associated with anti‐CD36

“…In 10 cases, patients had an adequate response to CD36‐negative PLTs; in one case this information was unavailable 7 . Recently, a sickle cell anemia patient undergoing stem cell transplantation responded adequately to CD36‐positive PLT transfusions, in spite of the presence of anti‐CD36 16 . In addition, at least eight clinically significant neonatal alloimmune thrombocytopenia cases and several cases of posttransfusion purpura, summarized by Curtis and coworkers 7 and Culler and coworkers, 16 have been attributed to anti‐CD36.…”